A comparative study of proton-pump inhibitor tests for chinese reflux patients in relation to the CYP2C19 genotypes

Journal of Clinical Gastroenterology

Volumn 43, Issue 10, 2009, Pages 920-925

  Tseng, Ping Huei ^a   Lee, Yi Chia ^a,b   Chiu, Han Mo ^a   Wang, Hsiu Po ^a   Lin, Jaw Town ^a,c   Wu, Ming Shiang ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c E DA HOSPITAL   (Taiwan)

Author keywords

CYP2C19; Gastroesophageal reflux disease; Pantoprazole; Proton pump inhibitor test; Rabeprazole

Indexed keywords

CYTOCHROME P450 2C19; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; 2 [[(2 PYRIDYL)METHYL]SULFINYL]BENZIMIDAZOLE DERIVATIVE; ANTIULCER AGENT; CYP2C19 PROTEIN, HUMAN; DIAGNOSTIC AGENT; UNSPECIFIC MONOOXYGENASE;

ADULT; ARTICLE; CHINESE; COMPARATIVE STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DISEASE SEVERITY; DRUG MEGADOSE; FEMALE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME; CHINA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GENETICS; LABORATORY DIAGNOSIS; METABOLISM; MIDDLE AGED; PREDICTION AND FORECASTING; RANDOMIZED CONTROLLED TRIAL; REFLUX ESOPHAGITIS; SENSITIVITY AND SPECIFICITY;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; ANTI-ULCER AGENTS; ARYL HYDROCARBON HYDROXYLASES; CHINA; ESOPHAGITIS, PEPTIC; FALSE POSITIVE REACTIONS; FEMALE; GASTROESOPHAGEAL REFLUX; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROTON PUMP INHIBITORS; SENSITIVITY AND SPECIFICITY;

EID: 74949100769     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCG.0b013e3181960628     Document Type: Article

References (55)

1. Vakil N, van Zanten SV, Kahrilas P, et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006; 101:1900-1920; quiz 1943.
2. Locke GR III, Talley NJ, Fett SL, et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted county, Minnesota. Gastroenterology. 1997;112: 1448-1456.
3. Fass R, Ofman JJ, Gralnek IM, et al. Clinical and economic assessment of the omeprazole test in patients with symptoms suggestive of gastroesophageal reflux disease. Arch Intern Med. 1999;159:2161-2168.
4. des Varannes SB, Sacher-Huvelin S, Vavasseur F, et al. Rabeprazole test for the diagnosis of gastro-oesophageal reflux disease: results of a study in a primary care setting. World J Gastroenterol. 2006;12:2569-2573.
5. Dickman R, Emmons S, Cui H, et al. The effect of a therapeutic trial of high-dose rabeprazole on symptom response of patients with non-cardiac chest pain: a randomized, double-blind, placebo-controlled, crossover trial. Aliment Pharmacol Ther. 2005;22:547-555.
6. Fass R, Ofman JJ, Sampliner RE, et al. The omeprazole test is as sensitive as 24-hours oesophageal pH monitoring in diagnosing gastro-oesophageal reflux disease in symptomatic patients with erosive oesophagitis. Aliment Pharmacol Ther. 2000;14:389-396.
7. Johnsson F, Weywadt L, Solhaug JH, et al. One-week omeprazole treatment in the diagnosis of gastro-oesophageal reflux disease. Scand J Gastroenterol. 1998;33:15-20.
8. Juul-Hansen P, Rydning A, Jacobsen CD, et al. High-dose proton-pump inhibitors as a diagnostic test of gastrooesophageal reflux disease in endoscopic-negative patients. Scand J Gastroenterol. 2001;36:806-810.
9. Numans ME, Lau J, de Wit NJ, et al. Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics. Ann Intern Med. 2004;140:518-527.
10. Schindlbeck NE, Klauser AG, Voderholzer WA, et al. Empiric therapy for gastroesophageal reflux disease. Arch Intern Med. 1995;155:1808-1812.
11. Vakil N. Review article: how valuable are proton-pump inhibitors in establishing a diagnosis of gastro-oesophageal reflux disease? Aliment Pharmacol Ther. 2005;22(suppl 1): 64-69.
12. Aanen MC, Weusten BL, Numans ME, et al. Diagnostic value of the proton pump inhibitor test for gastro-oesophageal reflux disease in primary care. Aliment Pharmacol Ther. 2006;24: 1377-1384.
13. Bate CM, Riley SA, Chapman RW, et al. Evaluation of omeprazole as a cost-effective diagnostic test for gastrooesophageal reflux disease. Aliment Pharmacol Ther. 1999;13: 59-66.
14. Ofman JJ, Dorn GH, Fennerty MB, et al. The clinical and economic impact of competing management strategies for gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2002;16:261-273.
15. Klotz U, Schwab M, Treiber G. CYP2C19 polymorphism and proton pump inhibitors. Basic Clin Pharmacol Toxicol. 2004; 95:2-8.
16. Chong E, Ensom MH. Pharmacogenetics of the proton pump inhibitors: a systematic review. Pharmacotherapy. 2003;23: 460-471.
17. Goldstein JA, Ishizaki T, Chiba K, et al. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics. 1997;7:59-64.
18. Li ZS, Zhan XB, Xu GM, et al. Effect of esomeprazole and rabeprazole on intragastric pH in healthy Chinese: an open, randomized crossover trial. J Gastroenterol Hepatol. 2007;22: 815-820.
19. Egan LJ, Myhre GM, Mays DC, et al. CYP2C19 pharmacogenetics in the clinical use of proton-pump inhibitors for gastro-oesophageal reflux disease: variant alleles predict gastric acid suppression, but not oesophageal acid exposure or reflux symptoms. Aliment Pharmacol Ther. 2003;17:1521-1528.
20. Furuta T, Shirai N, Watanabe F, et al. Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole. Clin Pharmacol Ther. 2002;72:453-460.
21. Lee YC, Lin JT, Wang HP, et al. Influence of cytochrome P450 2C19 genetic polymorphism and dosage of rabeprazole on accuracy of proton-pump inhibitor testing in Chinese patients with gastroesophageal reflux disease. J Gastroenterol Hepatol. 2007;22:1286-1292.
22. Dojo M, Azuma T, Saito T, et al. Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan. Dig Liver Dis. 2001;33:671-675.
23. Furuta T, Shirai N, Takashima M, et al. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin Pharmacol Ther. 2001;69: 158-168. (Pubitemid 32225416)
24. Gawronska-Szklarz B, Wrzesniewska J, Starzynska T, et al. Effect of CYP2C19 and MDR1 polymorphisms on cure rate in patients with acid-related disorders with Helicobacter pylori infection. Eur J Clin Pharmacol. 2005;61:375-379.
25. Kawabata H, Habu Y, Tomioka H, et al. Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin. Aliment Pharmacol Ther. 2003; 17:259-264.
26. Padol S, Yuan Y, Thabane M, et al. The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis. Am J Gastroenterol. 2006;101:1467-1475.
27. Schwab M, Schaeffeler E, Klotz U, et al. CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole-based quadruple therapy for eradication of Helicobacter pylori. Clin Pharmacol Ther. 2004; 76:201-209.
28. Horai Y, Kimura M, Furuie H, et al. Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes. Aliment Pharmacol Ther. 2001;15: 793-803.
29. Ishizaki T, Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors-emphasis on rabeprazole. Aliment Pharmacol Ther. 1999;13(suppl 3): 27-36.
30. Blume H, Donath F, Warnke A, et al. Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Saf. 2006; 29:769-784.
31. Meyer UA. Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs. Eur J Gastroenterol Hepatol. 1996;8(suppl 1): S21-S25.
32. Fock KM, Ang TL, Bee LC, et al. Proton pump inhibitors: do differences in pharmacokinetics translate into differences in clinical outcomes? Clin Pharmacokinet. 2008;47:1-6.
33. Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut. 1999;45: 172-180.
34. de Morais SM, Wilkinson GR, Blaisdell J, et al. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem. 1994;269: 15419-15422.
35. Gardner JD. How do I interpret a positive diagnostic test? Gastrointest Endosc. 2007;66:891-893.
36. Bruley des Varannes S. The proton-pump inhibitor test: pros and cons. Eur J Gastroenterol Hepatol. 2004;16:847-852.
37. Mones J. Diagnostic value of potent acid inhibition in gastro-oesophageal reflux disease. Drugs. 2005;65(suppl 1): 35-42.
38. Dupas JL, Houcke P, Samoyeau R. Pantoprazole versus lansoprazole in French patients with reflux esophagitis. Gastroenterol Clin Biol. 2001;25:245-250.
39. Johnsson F, Hatlebakk JG, Klintenberg AC, et al. One-week esomeprazole treatment: an effective confirmatory test in patients with suspected gastroesophageal reflux disease. Scand J Gastroenterol. 2003;38:354-359.
40. Xia HH, Lai KC, Lam SK, et al. Symptomatic response to lansoprazole predicts abnormal acid reflux in endoscopynegative patients with non-cardiac chest pain. Aliment Pharmacol Ther. 2003;17:369-377.
41. Li XQ, Andersson TB, Ahlstrom M, et al. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004;32:821-827.
42. Adachi K, Katsube T, Kawamura A, et al. CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole. Aliment Pharmacol Ther. 2000;14: 1259-1266.
43. Shirai N, Furuta T, Moriyama Y, et al. Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. Aliment Pharmacol Ther. 2001; 15:1929-1937. (Pubitemid 34014349)
44. Hu YM, Xu JM, Mei Q, et al. Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotype in healthy Chinese subjects. Acta Pharmacol Sin. 2005; 26:384-388.
45. Hu XP, Xu JM, Hu YM, et al. Effects of CYP2C19 genetic polymorphism on the pharmacokinetics and pharmacodynamics of omeprazole in Chinese people. J Clin Pharm Ther. 2007;32:517-524.
46. Hu YM, Mei Q, Xu XH, et al. Pharmacodynamic and kinetic effect of rabeprazole on serum gastrin level in relation to CYP2C19 polymorphism in Chinese Hans. World J Gastroenterol. 2006;12:4750-4753.
47. Hu YR, Qiao HL, Kan QC. Pharmacokinetics of lansoprazole in Chinese healthy subjects in relation to CYP2C19 genotypes. Acta Pharmacol Sin. 2004;25:986-990.
48. Furuta T, Sugimoto M, Shirai N, et al. CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor. Pharmacogenomics. 2007;8:1199-1210.
49. Horn J. Review article: relationship between the metabolism and efficacy of proton pump inhibitors-focus on rabeprazole. Aliment Pharmacol Ther. 2004;20(suppl 6):11-19.
50. Lim PW, Goh KL, Wong BC. CYP2C19 genotype and the PPIs-focus on rabeprazole. J Gastroenterol Hepatol. 2005; 20(suppl):S22-S28.
51. Kawamura M, Ohara S, Koike T, et al. The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism. Aliment Pharmacol Ther. 2003;17:965-973.
52. Sim SC, Risinger C, Dahl ML, et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther. 2006;79:103-113.
53. Baldwin RM, Ohlsson S, Pedersen RS, et al. Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers. Br J Clin Pharmacol. 2008;65:767-774.
54. Sugimoto K, Uno T, Yamazaki H, et al. Limited frequency of the CYP2C19*17 allele and its minor role in a Japanese population. Br J Clin Pharmacol. 2008;65:437-439.
55. Hunfeld NG, Mathot RA, Touw DJ, et al. Effect of CYP2C19*2 and *17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians. Br J Clin Pharmacol. 2008;65:752-760.